Université Cote d'Azur,
Institut de Recherche Cancer et Vieillissement de Nice (IRCAN)
UMR CNRS 7284/U Inserm 1081
hôte : Alexandre DAVID (IRCM)
Centre de Recherche en Biologie Cellulaire de Montpellier (CRBM)
Equipe "Dynamique du Cytosquelette et du Trafic Membranaire dans l'Adhérence"
CNRS UMR 5237
Hôte : Nathalie Bonnefoy (IRCM)
Group Leader, Tumor Immunotherapy and Microenvironment
Luxembourg Institute of Health, Department of Cancer Research
contact : Andrei Turtoi (IRCM)
Pediatric Cancer Metabolism Laboratory, Children's Research Center,
University of Zurich, 8032 Zurich, Suisse
hôte : Alexandre DAVID (IRCM)
Associate Professor,
Innate tumor Immunology laboratory
Oxford University, England
Dr Eileen Parkes is an early phase medical oncologist and associate professor at the University of Oxford. She completed her medical oncology training and PhD at Queens University Belfast before moving to Oxford in 2019. She leads early phase studies of novel IO, including STING agonsits, and is lead for Oxford Experimental Cancer Medicine Centre, focusing on translational research. Her lab team studies the tumour microenvironment of chromosomally unstable cancers, with a particular focus on cGAS-STING signalling, intending to identify novel therapeutic strategies for chromosomally unstable cancers including oesophageal adenocarcinomas.
host: Julien Faget (IRCM)
NYU Langone Medical Center, New York City (USA)
hôte : Alexandre David (IRCM)